Delving into the Latest Updates on Zhixiang (Shanghai) Medical Technology Co., Ltd. with Synapse

Overview

Basic Info

Introduction

Genrix (Shanghai) Biopharmaceutical Co., Ltd. was established in the year 2015. Operating as an innovative biopharmaceutical company propelled by antibody drug discovery technologies, it primarily concentrates on the therapeutic domains of autoimmune diseases, infectious diseases, and cancer. The company is actively engaged in the research, development, manufacturing, and commercialization of antibody-based therapeutics.

Tags

Otorhinolaryngologic Diseases

Congenital Disorders

Immune System Diseases

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	1
Infectious Diseases	1

Top 5 Drug Type	Count

Monoclonal antibody	1

Top 5 Target	Count

IL-4Rα(Interleukin-4 receptor subunit alpha)	1

主要目的：评价GR2001注射液在疑似破伤风暴露者中的有效性。次要目的：比较GR2001注射液与HTIG在疑似破伤风暴露者中的临床结局；比较GR2001注射液与HTIG的安全性；评价GR2001注射液在疑似破伤风暴露者中的药代动力学（PK）特征；评价GR2001注射液在疑似破伤风暴露者中的免疫原性。

[Translation]

Primary objective: To evaluate the effectiveness of GR2001 injection in patients with suspected tetanus exposure. Secondary objectives: To compare the clinical outcomes of GR2001 injection and HTIG in patients with suspected tetanus exposure; To compare the safety of GR2001 injection and HTIG; To evaluate the pharmacokinetic (PK) characteristics of GR2001 injection in patients with suspected tetanus exposure; To evaluate the immunogenicity of GR2001 injection in patients with suspected tetanus exposure.

Start Date03 Sep 2024

Sponsor / Collaborator

Chongqing Genrix Biopharmaceutical Co., Ltd.

[+1]

NCT06635798 / RecruitingPhase 3

A Multicentre, Randomized, Double-blind, Human Tetanus Immunoglobulin(HTIG) Controlled Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection for Indication of Prophylaxis Against Tetanus

The goal of this clinical trial is to compare the efficacy and safety of GR2001 injection with Human Tetanus Immunoglobulin(HTIG) in tetanus prophylaxis. Patients will receive either GR2001 injection or HTIG on study D0.

Start Date03 Sep 2024

Sponsor / Collaborator

Zhixiang (Shanghai) Medical Technology Co., Ltd.

NCT06566547 / RecruitingPhase 2

Single-Arm, Open, Multi-Center Phase II Clinical Trial of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma

All subjects will receive GR1803 injection until intolerable toxicity or investigator-assessed disease progression occurs (except in cases of disease progression due to discontinuation of the drug as a result of an adverse event) or until the subject has been administered the drug for 2 years or until the subject withdraws consent or until the investigator determines that the subject needs to be discontinued.

Start Date26 Aug 2024

Sponsor / Collaborator

Zhixiang (Shanghai) Medical Technology Co., Ltd.

100 Clinical Results associated with Zhixiang (Shanghai) Medical Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Zhixiang (Shanghai) Medical Technology Co., Ltd.

Login to view more data

2

Literatures (Medical) associated with Zhixiang (Shanghai) Medical Technology Co., Ltd.

02 Dec 2021·XenobioticaQ4 · MEDICINE

Evaluation of MTBH, a novel hesperetin derivative, on the activity of hepatic cytochrome P450 isoform in vitro and in vivo using a cocktail method by HPLC-MS/MS

Q4 · MEDICINE

Article

Author: Shen, Chenlin ; Huang, Xiaohui ; Fan, Yuru ; Zhang, Tianci ; Wang, Jie ; Song, Shuai ; Chen, Guanjun ; Zhang, Yilong ; Qin, Yan ; Li, Jun ; Dong, Haijun ; Wang, Sheng ; Sun, Jiayin ; Wang, Wei

1. 8-methylene-tert-butylamine-3',5,7-trihydroxy-4'-methoxyflavanone (MTBH), a novel hesperidin derivative, has potential in the prevention of hepatic disease, however, its effects on cytochrome P450 isoforms (CYP450s) remains unexplored. The purpose was to investigate the effects of MTBH on the mRNA, protein levels, and activities of six CYP450s (1A2, 2C11/9, 2D2/6, 3A1/4, 2C13/19, and 2E1) in vitro and in vivo.2. In vitro study, rat and human liver microsomes were adopted to elucidate the inhibitory effect of MTBH on six CYP450s using probe drugs. In vivo study, Sprague-Dawley male rats were treated with MTBH (25, 50, or 100 mg/kg for 28 consecutive days), phenobarbital (80 mg/kg for 12 consecutive days), or 0.5% CMC-Na solution (control group) by intragastric administration, then, the mRNA, protein levels and activities of liver CYP450s were analysed by real-time PCR, western blotting and probe-drug incubation systems, respectively.3. The in vitro study indicated that MTBH inhibits the activities of CYP3A1/4 and CYP2E1 in rat and human liver microsomes. In vivo data showed that MTBH inhibits mRNA, protein levels, and activities of CYP3A1 and CYP2E1 in medium- and high-dose MTBH groups.4. MTBH has the potential to cause drug-drug interactions when co-administered with drugs that are metabolised by CYP3A1/4 and CYP2E1.

01 Sep 2019·Biochemical and Biophysical Research Communications

Preclinical development of GR1501, a human monoclonal antibody that neutralizes interleukin-17A

Article

Author: Qian, Xuelong ; Yang, Jiaqian ; Chang, Zhiyuan ; Gao, Yuan ; Shi, Ke ; Xu, Qiang ; Shan, Yunlong ; Jin, Wei ; Luo, Qiong

Interleukin-17A (IL-17A) is a soluble pro-inflammatory cytokine, which is mainly secreted by Th17 cells. In humans, IL-17A mRNA and protein levels are increased in several autoimmune diseases, including psoriasis and rheumatoid arthritis. This study describes the preclinical in vitro and in vivo characterization of GR1501, a human IL-17A-neutralizing IgG4 monoclonal antibody. GR1501 binds human, rhesus and cynomolgus IL-17A with high affinity but does not bind to mouse IL-17A or other IL-17 family members. GR1501 effectively blocks the interaction between IL-17A and its receptor IL-17RA, thereby inhibiting IL-17A-induced CXCL1 and IL-6 release in cells and mice. In mouse air pouch model, GR1501 effectively inhibits IL-17A induced leukocytes infiltration into the air pouch. GR1501 also reduces joint swelling and inflammation in mouse arthritis model. These data suggest that GR1501 is a potent and selective IL-17A-neutralizing monoclonal antibody and will support the clinical investigation of this monoclonal antibody in psoriasis and rheumatoid arthritis.

100 Deals associated with Zhixiang (Shanghai) Medical Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Zhixiang (Shanghai) Medical Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

1

Login to view more data